The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment

Journal of Bone and Mineral Research

Volumn 31, Issue 3, 2016, Pages 650-656

  Pignolo, Robert J ^a,b   Bedford Gay, Christopher ^c   Liljesthröm, Moira ^c   Durbin Johnson, Blythe P ^d,e   Shore, Eileen M ^b   Rocke, David M ^d,e   Kaplan, Frederick S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c International FOP Association   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e University of California Davis   (United States)

Author keywords

CLINICAL TRIALS; EPIDEMIOLOGY; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FOP

Indexed keywords

ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; IBUPROFEN; MONTELUKAST; PREDNISONE;

ABDOMEN; ADOLESCENT; ADULT; AGED; ARTICLE; BACK; CHILD; CORTICOSTEROID THERAPY; ELBOW; FEMALE; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; HETEROTOPIC OSSIFICATION; HUMAN; JAW; KNEE; MAJOR CLINICAL STUDY; MALE; NECK; PAIN; PATIENT ATTITUDE; PHYSICAL MOBILITY; PROSPECTIVE STUDY; RECURRENT DISEASE; SHOULDER; SKELETON MALFORMATION; SWELLING; SYMPTOM; THORAX; ATTITUDE TO HEALTH; DEMOGRAPHY; DISABILITY; DISEASE COURSE; INFANT; INTERNATIONAL COOPERATION; MIDDLE AGED; OSSIFYING MYOSITIS; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DEMOGRAPHY; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFANT; INTERNATIONALITY; MALE; MIDDLE AGED; MYOSITIS OSSIFICANS; SYMPTOM FLARE UP; YOUNG ADULT;

EID: 84962900073     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2728     Document Type: Article

References (12)

1. Pignolo RJ, Shore EM, Kaplan FS., Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011; 6: 80.
2. Pignolo RJ, Shore EM, Kaplan FS., Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2: 437-48.
3. Shore EM, Xu M, Feldman GJ, et al., A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006 May;38(5): 525-7.
4. Kaplan FS, Pignolo RJ, Shore EM., From mysteries to medicines: drug development for fibrodysplasia ossificans progressive. Expert Opin Orphan Drugs. 2013 Aug;1(8): 637-49.
5. Cohen RB, Hahn GV, Tabas JA, et al., The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am. 1993 Feb; 75 (2): 215-9.
6. Rocke DM, Zasloff M, Peeper J, Cohen RB, Kaplan FS., Age- and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1994 Apr;(301): 243-8.
7. Groft SC, Rao G, Austin C, Gallin J., Workshop Summary. Workshop on natural history studies of rare diseases [Internet]. Bethesda: NIH (US); May 16-17, 2012 [cited 2015 Oct 26]. Available from: https://events-support.com/Documents/Summary-NHS.pdf.
8. Connor JM, Evans DA., Genetic aspects of fibrodysplasia ossificans progressiva. J Med Genet. 1982 Feb; 19 (1): 35-9.
9. Morales-Piga A, Kaplan FS., Osteochondral diseases and fibrodysplasia ossificans progressiva. Adv Exp Med Biol. 2010; 686: 335-48.
10. Lanchoney TF, Cohen RB, Rocke DM, Zasloff MA, Kaplan FS., Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr. 1995 May;126(5 Pt 1): 762-4.
11. Scarlett RF, Rocke DM, Kantanie S, Patel JB, Shore EM, Kaplan FS., Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 2004 Jun;(423): 275-9.
12. Kaplan FS, Shore EM, PS ignolo RJ, editors. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations [Internet]. The International Clinical Consortium on Fibrodysplasia Ossificans Progressiva. Vol. 4, pp P 1-100. Philadelphia, PA: The Center for Research in FOP and Related Disorders, The University of Pennsylvania School of Medicine (US); 2011 [cited 2015 Oct 26]. Available from: IR http://www.ifopa.org/living-with-fop-menu/doc-repository/doc-download/502-fop-treatment-guidelines-9-17-L15.html.